AZ-UNIVERSAL-ELECTRONICS
1.9.2021 22:12:11 CEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices, announced that Swiss telecommunications operator Salt , which provides innovative mobile, broadband and TV services, is one of the first providers to offer its voice-enabled Apple TV 4K remote control designed specifically for Multichannel Video Program Distributors (MVPDs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210901005858/en/
Available since June, Salt customers subscribing to the Salt Home broadband offer will automatically receive UEI’s Apple TV remote control with Apple TV 4K. Salt Home is the most competitive broadband proposition on the Swiss market offering up to 10 gigabits per second symmetric speed over FTTH including a TV service available on Apple TV as a set-top box. Existing customers can also purchase UEI’s Apple TV remote control as a standalone accessory in over 100 Salt stores throughout Switzerland and on Salt’s website .
“UEI has been a strong partner, helping us to provide our customers with a simple and quality remote control designed for Apple TV,” said Pascal Grieder, Salt’s CEO. “The collaboration with UEI across the project has been excellent.”
With Apple TV 4K, subscribers can watch live and on-demand content, as well as use the Apple TV app to watch Apple TV+, buy and rent thousands of movies and TV shows, and enjoy content from other streaming services. Customers can also access Apple Music, Apple Arcade and thousands of other apps, all through this powerful entertainment device built for the biggest screen in the home.
“We enjoyed working with Salt on this project as the Apple TV remote is one of our most exciting new offerings built with the customer in mind,” said Paul Arling, Chairman and CEO of UEI. “We look forward to opportunities to work with them in the future.”
UEI’s Apple TV remote combines Bluetooth Low Energy (BLE) connectivity together with Infrared to provide universal control, and features a range of innovative features and benefits to enhance the TV viewing experience:
- Advanced Search and Control: Customers can ask Siri to find and access content across live TV and streaming apps
- Enhanced Controls for Live TV : Dedicated program guide and channel up/down buttons provide easy and instant access to live TV viewing functions
- Whole Entertainment System Control: Modeless support and universal control of Apple TV, as well as televisions and audio devices from any brand or manufacturer
- Reliable and Secure Communication: Integrated design with UE878, UEI’s reliable and highly integrated BLE chipset optimized for voice control, and Apple’s MFi authentication chip for secure connectivity with Apple TV
- Premium Fit and Feel: Elegant and ergonomic form factor with hard-capped keys on metal domes for enhanced tactile feedback
- Automated Backlit Keys: Accelerometer and ambient light sensor to automatically backlight keys in low light environments when the remote is picked up or moved
About Universal Electronics Inc.
Founded in 1986, Universal Electronics Inc. (NASDAQ: UEIC) is the global leader in wireless universal control solutions for home entertainment and smart home devices. We design, develop, manufacture, ship and support control and sensor technology solutions and a broad line of universal control systems, audio video accessories, and intelligent wireless security and smart home products. Our products and solutions are used by the world's leading brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. For more information, visit www.uei.com .
Apple, Apple TV and Siri are trademarks of Apple Inc. and are not affiliated with UEI. All other trademarks appearing herein are the property of their respective owners.
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery and market acceptance of products and technologies identified in this release; the purchasing by Salt and other MVPDs of the products identified in this release in the quantities anticipated by management; the continued penetration and growth of UEI voice recognition technology and other products and consumer technologies identified in this release; and other factors described in UEI’s filings with the Securities and Exchange Commission. The actual results that UEI achieves may differ materially from any forward-looking statement due to such risks and uncertainties. UEI undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005858/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom